Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Specialised Therapeutics Acquires Commercialisation Rights for New Motor Neuron Disease Therapy

Monday, August 28, 2023

Specialised Therapeutics has recently announced a collaboration with Treeway to bring a new therapy TW001 to Australia and New Zealand for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the most common form of Motor Neurone Disease (MND).

Under the terms of agreement, Specialised Therapeutics takes charge of various aspects such as marketing, regulatory processes, and distribution of TW001 for ALS/MND in Australia and New Zealand.

TW001, the innovative therapy, is an oral formulation of edaravone. Its mechanism of action involves reducing the oxidative damage that contributes to the death of neurons in ALS. Currently, TW001 is undergoing evaluation in a crucial phase III clinical trial called ADORE, being conducted at nearly 40 global sites.

Amyotrophic Lateral Sclerosis (ALS) is a prevalent motor neuron disease marked by the progressive degeneration of motor neurons in the spinal cord and brain. This degeneration leads to gradual paralysis, often resulting in death within 2 to 5 years after diagnosis.

ALS is relatively rare disease affecting individuals aged between 40 to 70, with slightly more cases occurring in men than in women. While 10-15 percent of cases have a genetic or familial link, the remaining 85-90 percent are classified as sporadic cases, where the exact cause is not yet known.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024